Harbour BioMed
Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer.
Launch date
Employees
Market cap
AUD155m
Enterprise valuation
AUD47m (Public information from Sep 2024)
Share price
HKD1.23 2142.HK
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.4m | 14.1m | 4.3m | 40.7m | 89.5m | 659m | 930m |
| % growth | - | 160 % | (69 %) | 844 % | 120 % | 636 % | 41 % |
| EBITDA | (62.9m) | (291m) | (131m) | (115m) | 32.2m | - | - |
| % EBITDA margin | (1161 %) | (2062 %) | (3042 %) | (284 %) | 36 % | - | - |
| Profit | (67.5m) | (296m) | (138m) | (137m) | 22.8m | - | - |
| % profit margin | (1245 %) | (2101 %) | (3198 %) | (337 %) | 25 % | - | - |
| R&D budget | 49.5m | 55.2m | 107m | 135m | 45.1m | - | - |
| R&D % of revenue | 913 % | 392 % | 2486 % | 332 % | 50 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
$50.0m | Series A | ||
| N/A | N/A | Series A | |
* | $85.0m | Series B | |
* | $75.0m | Series B | |
$103m | Series C | ||
| N/A | $221m | IPO | |
| Total Funding | AUD483m | ||
Related Content
Recent News about Harbour BioMed
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Harbour BioMed
Edit
ACQUISITION by Harbour BioMed Dec 2016